8-K: Genprex Regains Nasdaq Bid Price Compliance, Extends Equity Exception

Genprex, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement and received an extension until December 31, 2025, to meet the minimum stockholders' equity requirement.

Summary

• Genprex, Inc. (GNPX) was formally notified on November 25, 2025, that it has regained compliance with the Nasdaq $1.00 Minimum Bid Price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The Nasdaq Hearings Panel approved an exception for the company until December 31, 2025, to demonstrate long-term compliance with the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)).
• The Panel has discretion to grant a further extension for continued listing through February 9, 2026, upon the company's request.
• The company believes it will need to engage in additional capital raising transactions to regain compliance with the stockholders' equity requirement.

Sentiment

Score: 6

Explanation: The company successfully addressed one Nasdaq listing deficiency (bid price) and received an extension for another (stockholders' equity). However, the continued non-compliance with the equity requirement and the stated need for future capital raises, with no guarantee of success, temper the overall positive news.

Positives

• Regained compliance with the Nasdaq $1.00 Minimum Bid Price requirement.
• Received an extension until December 31, 2025, to comply with the minimum stockholders' equity requirement.
• The Nasdaq Panel has discretion to grant a further extension until February 9, 2026, upon company request.

Negatives

• Still not in compliance with the Nasdaq minimum stockholders' equity requirement.
• Requires additional capital raising transactions to achieve compliance, with no guarantee of availability or acceptable terms.
• The Nasdaq Panel reserves the right to reconsider the exception based on future events.

Risks

• No assurance that the Nasdaq Panel will exercise its discretion to grant an extension beyond December 31, 2025, for the stockholders' equity requirement.
• No guarantee that necessary capital raising transactions will be available on terms acceptable to the company, or at all.
• The Panel may reconsider the terms of the exception based on any event, condition, or circumstance that would make continued listing inadvisable or unwarranted.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, as detailed in the company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company intends to provide prompt notification to the Nasdaq Panel of any significant events and may request a further extension beyond December 31, 2025, if needed. It anticipates needing additional capital raising transactions to regain compliance with the stockholders' equity requirement.

Management Comments

• The Company believes it will need to engage in additional capital raising transactions to regain compliance with the Stockholders Equity Requirement.
• The Company fully intends to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception.

Industry Context

This filing is highly specific to Genprex's compliance with Nasdaq listing rules and does not provide broader industry context or trends. It reflects a common challenge for smaller, often pre-revenue, biotechnology companies to maintain listing standards, particularly regarding bid price and equity.

Stakeholder Impact

• Shareholders: Potential positive impact from regaining bid price compliance and avoiding immediate delisting. However, dilution risk from future capital raises and ongoing uncertainty regarding the stockholders' equity requirement remain.
• Employees: No direct impact mentioned, but continued listing provides stability.

Next Steps

• Provide prompt notification to the Nasdaq Panel of any significant events that occur.
• Potentially request a further extension beyond December 31, 2025, to regain compliance with the stockholders' equity requirement.
• Engage in additional capital raising transactions to regain compliance with the stockholders' equity requirement.

Key Dates

Recommendation

While Genprex has successfully regained compliance with Nasdaq's minimum bid price requirement and secured an extension for the stockholders' equity rule, significant uncertainty persists. The company explicitly states the need for additional capital raising, which carries inherent risks of dilution and availability. The Nasdaq Panel also retains the right to reconsider the exception. Given these mixed signals – a positive step in compliance balanced by ongoing financial challenges and future capital raise dependency – a "hold" recommendation is appropriate. Investors should monitor the company's progress on the stockholders' equity requirement and the success of any future financing efforts before making further investment decisions.

Keywords

Genprex, GNPX, Nasdaq, Listing Compliance, Minimum Bid Price, Stockholders Equity, Capital Raise, SEC Filing, 8-K, Delisting Risk